Reviparin sodium explained

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).

Medical uses

• Prevention of blood clots
• Prophylaxis of perioperative thromboembolism^{[1] [2]}
• Treatment of DVT with or without pulmonary embolism (PE)^[3]
• Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)^{[4] [5]}

Chemistry

Reviparin is a low molecular weight heparin obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.

External links

• • Yusuf S, Mehta SR, Xie C, etal . Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation . JAMA . 293 . 4 . 427–35 . 2005 . 15671427 . 10.1001/jama.293.4.427. free .

Notes and References

1. Kakkar VV, Cohen AT, Mohamed MS . Patients at risk of venous thromboembolism--clinical results with reviparin . Thromb. Res. . 81 . 2 Suppl . S39–45 . 1996 . 8822126 . 10.1016/0049-3848(95)00228-6 .
2. Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E . Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery . Semin. Thromb. Hemost. . 25 Suppl 3 . 79–82 . 1999 . 10549720 .
3. Gore M, Kelkar P, Rege N, Ross C . Reviparin sodium clivarine: a review of its therapeutic use . J Indian Med Assoc . 102 . 10 . 589–90, 592 . October 2004 . 15887830 .
4. Preisack MB, Karsch KR . Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty . Blood Coagul. Fibrinolysis . 4 Suppl 1 . S55–8; discussion S59–60 . December 1993 . 8180331 .
5. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R . Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation . J. Am. Coll. Cardiol. . 28 . 6 . 1437–43 . November 1996 . 8917255 . 10.1016/s0735-1097(96)00343-9. 1765/55740 . free .